Europe PMC｜液体治疗与平衡晶体液· Kashani K, Selewski DT, Gist KM, Ostermann M, Mehta RL, Ronco C, Bagshaw SM, MacLaren G, Askenazi DJ, Rintoul NE, Singh G, Kaddourah A.·· 2026-09-10AI 评分24
ADQI与ELSO联合共识会议工作组声明：ECMO患者AKI与CRRT的流行病学、危险因素及结局
Epidemiology, Risk Factors and Outcomes of AKI and CRRT in Patients on ECMO: Workgroup Statements from the Joint Acute Disease Quality Initiative (ADQI) and Extracorporeal Life Support Organization (ELSO) Consensus Conference on ECMO, AKI, fluid management and CRRT.
AI 导读
ADQI与ELSO联合共识会议发布工作组声明，聚焦ECMO患者急性肾损伤（AKI）与连续性肾脏替代治疗（CRRT）的流行病学、危险因素及结局。ECMO患者AKI发生率为40-80%，约40-50%接受CRRT，二者均与死亡率升高、支持时间延长及远期慢性肾病风险独立相关。会议强调统一定义、识别可干预危险因素、优化CRRT策略，并呼吁开展前瞻性多中心试验与生物标志物验证。
来源：Europe PMC｜液体治疗与平衡晶体液 · pubmed.ncbi.nlm.nih.gov